SciRhom Raises €63M in Series A Funding for Autoimmune Therapy Development

SciRhom raises EUR 63M in Series A Funding

SciRhom, a Munich-based biopharmaceutical company, has secured EUR 63M in Series A funding to advance their therapeutic strategy in autoimmune disorders. With a focus on developing iRhom2 antibodies, SciRhom aims to provide relief to patients suffering from conditions such as rheumatoid arthritis and inflammatory bowel disease.

Funding Amount: EUR 63 million

Industry: Biotechnology Research

Employee Count: 2-10

CEO: Jan Poth (CEO Linkedin)

What SciRhom needs to buy: Companies specializing in clinical research and development services, manufacturing and supply chain solutions, and regulatory and compliance support are ideal partners for SciRhom. These collaborations will help accelerate the development, production, and approval processes for their therapeutic antibodies, ultimately benefiting patients and healthcare providers in the autoimmune disorder space.